This content is machine translated Type 2 diabetes: current trends Dual GIP/GLP-1 receptor agonist as an innovative therapeutic option The goals of individualized diabetes treatment today are not limited to achieving glycemic control, but many blood glucose-lowering drugs have clinically relevant additional benefits. Incretin-based therapies are particularly interesting for…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
